CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -0.32: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
405.80MUSDvs all stocks (USD)
Revenue (TTM)
109.16MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.56xvs all stocks
52-Week Change
291.30%vs all stocks
Market Capitalization
405.80MUSDvs all stocks (USD)
Enterprise Value
319.02MUSDvs all stocks (USD)
Forward P/E
-4.92xvs Biotechnology peers
Price to Sales (TTM)
3.72xvs Biotechnology peers
Price to Book (MRQ)
1.53xvs Biotechnology peers
Enterprise to Revenue
2.92xvs Biotechnology peers
Enterprise to EBITDA
-3.14xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-9.62%vs Biotechnology peers
Return on Assets (TTM)
-22.28%vs Biotechnology peers
Return on Equity (TTM)
-42.67%vs Biotechnology peers
Revenue (TTM)
109.16MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.26USDUpdated Jul 19, 2026Gross Profit (TTM)
-86.19MUSDvs all stocks (USD)
EBITDA (TTM)
9.36MUSDvs all stocks (USD)
Net Income (TTM)
-107.78MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-94.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-53.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
109.16MUSDFY2025 · Dec 31, 2025Operating Income
-10.51MUSDvs all stocks (USD)
Pre-tax Income
-9.65MUSDFY2025 · Dec 31, 2025Income Tax Expense
-68.00KUSDFY2025 · Dec 31, 2025Net Income
-9.58MUSDFY2025 · Dec 31, 2025EBIT
-10.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
9.36MUSDFY2025 · Dec 31, 2025Research & Development
95.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
24.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.35MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.58MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-106.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-107.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
65.01MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.58MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
13.10MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-73.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.84MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-4.02MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.56MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-114.14MUSDFY2025 · Dec 31, 2025Capital Expenditures
-848.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-51.17MUSDFY2025 · Dec 31, 2025Sale of Investments
159.52MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.50MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
173.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
180.10MSharesUpdated Jul 19, 2026Float Shares
97.71MSharesUpdated Jul 19, 2026Shares Short
23.46MSharesUpdated Jul 19, 2026Short Ratio
12.00daysvs all stocks
Short % of Shares Outstanding
13.10%vs all stocks
% Held by Insiders
8.20%vs all stocks
% Held by Institutions
77.92%vs all stocks
Total Cash (MRQ)
134.80MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7470USDUpdated Jul 19, 2026Total Debt (MRQ)
48.02MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1814xvs Biotechnology peers
Current Ratio (MRQ)
10.25xvs Biotechnology peers
Book Value per Share (MRQ)
1.47USDUpdated Jul 19, 2026Total Assets
223.70MUSDvs all stocks (USD)
Total Current Assets
120.77MUSDFY2025 · Dec 31, 2025Total Liabilities
64.77MUSDFY2025 · Dec 31, 2025Total Non-current Assets
102.94MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
44.54MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
61.85MUSDFY2025 · Dec 31, 2025Other Short-term Investments
55.26MUSDFY2025 · Dec 31, 2025Accounts Payable
4.77MUSDFY2025 · Dec 31, 2025Short-term Debt
3.32MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
3.78MUSDFY2025 · Dec 31, 2025Long-term Debt
40.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-791.92MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
158.94MUSDvs all stocks (USD)
52-Week Low
0.4350USDUpdated Jul 19, 202652-Week High
3.04USDUpdated Jul 19, 202652-Week Change
291.30%vs all stocks
Beta
1.56xvs all stocks
50-Day MA
2.28USDUpdated Jul 19, 2026200-Day MA
1.68USDUpdated Jul 19, 2026Avg 10-Day Volume
1.25MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.75MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.13USDUpdated Jul 19, 2026Other Income / Expense
-6.49MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
High Equity Share With Elevated Lease Share of Assets
Little debt against its assets, but leases are a large share of what it holds.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.25Altman Z-Score: -0.32
Financial Health
Altman Z-Score -0.32: distress zoneCritical
Altman Z-Score: -0.32
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Inox India Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
DK Tech Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Travere Therapeutics Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated